中外研究人員7月31日在英國(guó)著名學(xué)術(shù)雜志《自然—生物技術(shù)》（Nature Biotechnology）網(wǎng)絡(luò)版上說,，他們已完成對(duì)中國(guó)倉(cāng)鼠卵巢細(xì)胞系的基因組測(cè)序,。
中國(guó)倉(cāng)鼠卵巢細(xì)胞系對(duì)生物制藥意義重大。全球藥物蛋白每年的市場(chǎng)銷售額約為990億美元,，其中至少70%的藥物蛋白來源于中國(guó)倉(cāng)鼠卵巢細(xì)胞系,。
中國(guó)深圳華大基因研究院與美國(guó)GT生命科學(xué)公司的研究人員在論文中說，他們采用新一代測(cè)序技術(shù)對(duì)中國(guó)倉(cāng)鼠卵巢K1細(xì)胞系進(jìn)行測(cè)序,、組裝，共預(yù)測(cè)了2.4萬多個(gè)基因,，并對(duì)預(yù)測(cè)的基因進(jìn)行了功能注釋,。
該研究報(bào)告的第一作者徐訊說，中國(guó)倉(cāng)鼠卵巢細(xì)胞系基因組測(cè)序的完成將有助于從基因水平進(jìn)一步了解其細(xì)胞的功能,，從而促進(jìn)對(duì)該細(xì)胞系的優(yōu)化應(yīng)用,，降低生產(chǎn)成本。
華大基因研究院副院長(zhǎng)王俊認(rèn)為,，中國(guó)倉(cāng)鼠卵巢細(xì)胞系基因組測(cè)序的完成為今后系統(tǒng)且高效地研究更多細(xì)胞系提供了基礎(chǔ),，這是將基因組學(xué)應(yīng)用于生物醫(yī)藥生產(chǎn)的重要一步。(生物谷 Bioon.com)
doi:10.1038/nbt.1932
PMC:
PMID:
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xun Xu; Harish Nagarajan; Nathan E Lewis; Shengkai Pan; Zhiming Cai; Xin Liu; Wenbin Chen; Min Xie; Wenliang Wang; Stephanie Hammond; Mikael R Andersen; Norma Neff; Benedetto Passarelli; Winston Koh; H Christina Fan; Jianbin Wang; Yaoting Gui; Kelvin H Lee; Michael J Betenbaugh; Stephen R Quake; Iman Famili; Bernhard O Palsson; Jun Wang
Chinese hamster ovary (CHO)–derived cell lines are the preferred host cells for the production of therapeutic proteins. Here we present a draft genomic sequence of the CHO-K1 ancestral cell line. The assembly comprises 2.45 Gb of genomic sequence, with 24,383 predicted genes. We associate most of the assembled scaffolds with 21 chromosomes isolated by microfluidics to identify chromosomal locations of genes. Furthermore, we investigate genes involved in glycosylation, which affect therapeutic protein quality, and viral susceptibility genes, which are relevant to cell engineering and regulatory concerns. Homologs of most human glycosylation-associated genes are present in the CHO-K1 genome, although 141 of these homologs are not expressed under exponential growth conditions. Many important viral entry genes are also present in the genome but not expressed, which may explain the unusual viral resistance property of CHO cell lines. We discuss how the availability of this genome sequence may facilitate genome-scale science for the optimization of biopharmaceutical protein production.
